Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Applications' CEO Dispels Rumors of Sale

Premium

PALO ALTO, Calif.--Dispelling industry rumors that Molecular Applications Group is up for sale, Debbie Yu, acting CEO, said the company is seeking partnerships, but not a buyer. "MAG is definitely not on the block, but we are pursuing conversations with a number of strategic players because it is a cornerstone of our business plan to do that," Yu said. Rumors about the company's financial health heated up recently after John Andrews, executive vice-president and chief operating officer, departed from the company.

"I hear the same rumors," Yu said, "but we have not hired a bank to sell the company, we have not made any strategic efforts to sell, we have a CEO search under way, and we are planning to do another round of financing to raise $5-$10 million in the next few months. These are things you do when you're keeping a company going."

Still, Yu acknowledged, "You can never say never. Most companies in our space will either die or merge. Very few bioinformatics companies are ever going to go public."

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.